Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
25 Jun 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
CHF 100.00
30.6% undervalued intrinsic discount08 Aug
CHF 69.40
1Y
-13.4%7D
5.2%